Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa Drew

Showing results (21-30 of 41) with videos related to

Pageof 5
Sort By:
Bioorganic & Medicinal Chemistry Letters|July 12, 2013
Mitigation of cardiovascular toxicity in a series of CSF-1R inhibitors, and the identification of AZD7507David A Scott, Les A Dakin, Kevin Daly, et al.
Journal of Medicinal Chemistry|October 18, 2019
Discovery of a Series of 5-Azaquinazolines as Orally Efficacious IRAK4 Inhibitors Targeting MyD88<sup>L265P</sup> Mutant Diffuse Large B Cell LymphomaSébastien L Degorce, Rana Anjum, Andrew Bloecher, et al.
Blood|December 1, 2018
Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomasRaphael Koch, Amanda L Christie, Jennifer L Crombie, et al.
The Journal of Clinical Investigation|December 1, 2021
Antisense oligonucleotide therapy reduces seizures and extends life span in an SCN2A gain-of-function epilepsy modelMelody Li, Nikola Jancovski, Paymaan Jafar-Nejad, et al.
Science Translational Medicine|January 27, 2012
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung CancersRyohei Katayama, Alice T Shaw, Tahsin M Khan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 9, 2019
AZD4573 Is a Highly Selective CDK9 Inhibitor That Suppresses MCL-1 and Induces Apoptosis in Hematologic Cancer CellsJustin Cidado, Scott Boiko, Theresa Proia, et al.
Nature Communications|November 16, 2019
Targeting melanoma's MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitorsMatthew J Sale, Emma Minihane, Noel R Monks, et al.
Bioorganic & Medicinal Chemistry Letters|December 23, 2008
Identification of amidoheteroaryls as potent inhibitors of mutant (V600E) B-Raf kinase with in vivo activityPaul D Lyne, Brian Aquila, Donald J Cook, et al.
NPJ Precision Oncology|December 27, 2022
The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cellsSteven W Criscione, Matthew J Martin, Derek B Oien, et al.
Journal of Medicinal Chemistry|February 13, 2013
Discovery and optimization of a novel series of potent mutant B-Raf(V600E) selective kinase inhibitorsMelissa M Vasbinder, Brian Aquila, Martin Augustin, et al.
Pageof 5

Showing results (21-30 of 41) with videos related to

Sort By:
Pageof 5
Bioorganic & Medicinal Chemistry Letters|July 12, 2013
Mitigation of cardiovascular toxicity in a series of CSF-1R inhibitors, and the identification of AZD7507David A Scott, Les A Dakin, Kevin Daly, et al.
Journal of Medicinal Chemistry|October 18, 2019
Discovery of a Series of 5-Azaquinazolines as Orally Efficacious IRAK4 Inhibitors Targeting MyD88<sup>L265P</sup> Mutant Diffuse Large B Cell LymphomaSébastien L Degorce, Rana Anjum, Andrew Bloecher, et al.
Blood|December 1, 2018
Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomasRaphael Koch, Amanda L Christie, Jennifer L Crombie, et al.
The Journal of Clinical Investigation|December 1, 2021
Antisense oligonucleotide therapy reduces seizures and extends life span in an SCN2A gain-of-function epilepsy modelMelody Li, Nikola Jancovski, Paymaan Jafar-Nejad, et al.
Science Translational Medicine|January 27, 2012
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung CancersRyohei Katayama, Alice T Shaw, Tahsin M Khan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 9, 2019
AZD4573 Is a Highly Selective CDK9 Inhibitor That Suppresses MCL-1 and Induces Apoptosis in Hematologic Cancer CellsJustin Cidado, Scott Boiko, Theresa Proia, et al.
Nature Communications|November 16, 2019
Targeting melanoma's MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitorsMatthew J Sale, Emma Minihane, Noel R Monks, et al.
Bioorganic & Medicinal Chemistry Letters|December 23, 2008
Identification of amidoheteroaryls as potent inhibitors of mutant (V600E) B-Raf kinase with in vivo activityPaul D Lyne, Brian Aquila, Donald J Cook, et al.
NPJ Precision Oncology|December 27, 2022
The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cellsSteven W Criscione, Matthew J Martin, Derek B Oien, et al.
Journal of Medicinal Chemistry|February 13, 2013
Discovery and optimization of a novel series of potent mutant B-Raf(V600E) selective kinase inhibitorsMelissa M Vasbinder, Brian Aquila, Martin Augustin, et al.
Pageof 5